First, OCT4 and NANOG are not specific biomarkers for RCC or they do not play dominant roles in the tumorigeness of RCC, but according to Bussolati's [11] report, OCT4 and NANOG are expressed in tumor-initiating CD105+ stem cells in human renal carcinomas. The gene discussed is NANOG; the disease is renal cell adenocarcinoma.